Brussels bets on biotech. But will three breakthrough medicines a year be enough?

EU PERSPECTIVES - Brussels is willing to accept higher costs for healthcare systems to win the global biotech race. A new EU incentive would extend intellectual property rights for a handful of cutting-edge drugs, delaying cheaper biosimilars at an estimated €615 million a year. Europe is betting the trade-off will be worth it. Read more

Photo: Unsplash